1331732-05-8 Usage
Type
Synthetic anabolic steroid
Derivation
Derived from dihydrotestosterone
Structural Modifications
a. Methyl group at the C17α position
b. Oxygen atom replacing the carbon at the C2 position
Medical Uses
a. Promoting weight gain in conditions like trauma, surgery, chronic infection, or prolonged corticosteroid treatment
b. Treating osteoporosis
c. Offsetting protein catabolism caused by prolonged corticosteroid therapy
Performance-Enhancing Use
Used to increase muscle mass and strength in certain sports
Legal Status in Sports
Banned by most athletic organizations due to potential for misuse and adverse health effects
Adverse Effects
Potential for misuse and negative health consequences
Molecular Weight
302.45 g/mol
Appearance
White to off-white crystalline powder
Solubility
Soluble in chloroform, slightly soluble in alcohol, and practically insoluble in water
Melting Point
160-162°C
Dosage Forms
Available as oral tablets and sometimes in injectable form
Mechanism of Action
Binds to androgen receptors, promoting protein synthesis and muscle growth
Half-Life
Approximately 9.1 hours
Elimination
Primarily metabolized in the liver and excreted in urine
Drug Interactions
May interact with other medications, including corticosteroids, anticoagulants, and certain antibiotics
Precautions
Not recommended for use in children, pregnant or breastfeeding women, or individuals with liver disease or cardiovascular issues.
Check Digit Verification of cas no
The CAS Registry Mumber 1331732-05-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,1,7,3 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1331732-05:
(9*1)+(8*3)+(7*3)+(6*1)+(5*7)+(4*3)+(3*2)+(2*0)+(1*5)=118
118 % 10 = 8
So 1331732-05-8 is a valid CAS Registry Number.
1331732-05-8Relevant articles and documents
Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)
Buzzetti,Di Salle,Longo,Briatico
, p. 527 - 532 (1993)
Exemestane (6-methylenandrosta-1,4-diene-3,17-dione; FCE 24304) is an orally active irreversible aromatase inhibitor which is in phase II clinical evaluation for the potential therapy of postmenopausal breast cancer. A series of exemestane analogs, with modifications at the 6-methylene group and with additional reduction at the 17-keto group, were synthesized as potential metabolites and tested in vitro for their effect on human placental aromatase. All these new analogs were found to be less potent in inhibiting aromatase than exemestane. The most effective compound was the 17β-hydroxy- derivative (compound 2), which is 2.6-fold less potent than exemestane [50% inhibitory concentration (IC50) 69 and 27 nM, respectively]. The various C- 6 modified derivatives of the 17-oxo series were found to inhibit the aromatase enzyme in the following descending order: 6-methylene (exemestane) > 6-spirooxirane (6) > 6β-hydroxymethyl (11) > 6-hydroxymethyl (7) > 6β- carboxy (13), showing IC50 values of 27, 206, 295, 2,300, and 7,200 nM, respectively. The 17β-hydroxy analogs of some of the above mentioned compounds were also synthesized (3, 4, 12) and found to be 3-8-fold less potent than the corresponding 17-keto analogs.
